Skip to main content
Premium Trial:

Request an Annual Quote

Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.

The contractor, Palmetto GBA, has expanded its coverage policy for all qualified Medicare patients to include those with ductal carcinoma in situ, or DCIS, Genomic Health said. The coverage policy took effect May 8.

The Redwood City, Calif.-based company said that detection of DCIS is increasing in the US with more than 50,000 patients diagnosed each year. The Oncotype DX DCIS Score predicts 10-year local recurrence, DCIS or invasive carcinoma, based on the patient's underlying tumor biology, Genomic Health said.

The company last week reported that revenues in the first quarter increased 8 percent year over year driven by adoption of its Onctotype DX products.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more